Unleashing Xeris Biopharma's (XERS) Q4 Opportunities: Analyzing Wall Street Projections for Essential Metrics

Xeris Biopharma Set to Announce Quarterly Results

Xeris Biopharma (XERS) is preparing to release its quarterly financial report, with analysts projecting earnings per share of $0.03. This figure marks a 200% increase compared to the same period last year. Revenue is anticipated to reach $81.43 million, reflecting a 35.5% rise year over year.

Over the past month, analysts have maintained their consensus estimate for Xeris Biopharma’s earnings per share, indicating a stable outlook and a collective reassessment of their earlier forecasts.

The Importance of Earnings Estimate Revisions

Before a company discloses its earnings, it is crucial to consider any updates to analyst projections. These revisions often serve as a key indicator of how investors might react to the stock. Research consistently shows a strong correlation between changes in earnings estimates and short-term stock price movements.

While consensus estimates for earnings and revenue provide a general sense of company performance, a closer look at forecasts for specific business metrics can offer deeper insights into the company’s operations.

Wall Street Forecasts for Key Xeris Biopharma Metrics

• Product Revenue – Gvoke: Analysts expect this segment to generate $26.45 million, representing a 13.7% increase from the previous year’s quarter.
• Product Revenue – Keveyis: Forecasts suggest revenue will reach $43.67 million, a substantial 292.6% jump year over year.
• Revenue – Royalty, Contract, and Other: This category is projected at $1.02 million, which would be a 67.2% decrease compared to the prior year.
• Product Revenue, Net: Analysts anticipate $81.19 million, up 42.4% from the same quarter last year.
• Product Revenue – Recorlev: Expected to total $11.07 million, reflecting a 51.1% decline year over year.

Recent Stock Performance and Outlook

In the past month, Xeris Biopharma’s share price has declined by 7%, while the Zacks S&P 500 composite index has edged up by 0.6%. With a Zacks Rank of #3 (Hold), XERS is expected to generally track the broader market’s movement in the near future.

New Release: Zacks Top 10 Stocks for 2026

There’s still time to get early access to Zacks’ top 10 stock picks for 2026. Curated by Zacks Director of Research Sheraz Mian, this portfolio has delivered impressive and consistent results.

Since its inception in 2012 through November 2025, the Zacks Top 10 Stocks portfolio has achieved a remarkable gain of +2,530.8%, far outpacing the S&P 500’s +570.3% return.

Sheraz Mian has reviewed 4,400 companies covered by the Zacks Rank system and selected the top 10 stocks to buy and hold for 2026. You can still be among the first to discover these newly released picks with significant growth potential.

Additional Resources

Looking for more stock recommendations from Zacks Investment Research? Download the report on the 7 Best Stocks for the Next 30 Days for free.